FDA: Modeling, simulation offer opportunity to advance public health

Modeling and simulation are valuable research and product development tools that are helping to advance regulatory science, according to the FDA.
The FDA is using modeling and simulation to help achieve its objectives of improving health care, broadening access and advancing public health goals, Tina Morrison, PhD, chair of FDA’s agency-wide modeling and simulation working group and regulatory advisor of computational modeling for FDA’s Office of Device Evaluation, said at an FDA Grand Rounds meeting.
‘Investment to the future’
Modeling and simulation can help predict

Full Story →